Tech Company Financing Transactions
DNAlite Therapeutics Funding Round
Berkeley Catalyst Fund, Blue Bear Capital and BrightGene participated in a $1.5 million Seed funding round for DNAlite Therapeutics. The round was announced on 8/9/2018.
Transaction Overview
Company Name
Announced On
8/9/2018
Transaction Type
Venture Equity
Amount
$1,500,000
Round
Seed
Investors
Proceeds Purpose
The proceeds of the round will be used to continue development of gastrointestinal tract gene therapy treatments for patients who suffer from genetic intestinal diseases, utilizing DNAlite's proprietary delivery platform technology.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
455 Mission Bay Blvd. South
San Francisco, CA 94158
USA
San Francisco, CA 94158
USA
Phone
Undisclosed
Website
Email Address
Overview
DNAlite Therapeutics, Inc. is an early-stage preclinical biotechnology company committed to bringing the next-generation of drugs to organs protected by mucus barriers.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Mubhij Ahmad
Chief Scientific Officer
Timothy Day
Browse more venture capital transactions:
Prev: 8/9/2018: Professional Fighters League venture capital transaction
Next: 8/9/2018: Abrexa Pharmaceuticals venture capital transaction
Share this article
About Database of VC Transactions
We do our best to report on all VC transactions involving tech companies. VC investment data records on this site are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs